Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
United Laboratories International HoldingsULIHF 90 Cyclically Adjusted PB Ratio is 1.19 as of Aug. 20, 2026, which is 14% below its 10-year median of 1.38. GuruFocus rates ULIHF with a GF Score™ of 90/100 and a GF Value™ of $1.24. The stock has 5 warning signs investors should review. Among 690 Drug Manufacturers companies, United Laboratories International Holdings ranks better than 59.57% on this metric.
ULIHF's Cyclically Adjusted PB Ratio is ranked better than 59.57% of 690
companies
in the Drug Manufacturers industry
Industry Median: 1.74
vs ULIHF: 1.35
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.
United Laboratories International Holdings's adjusted book value per share data of for the fiscal year that ended in Dec25 was $1.252. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $1.04 for the trailing ten years ended in Dec25.
Shiller PE for Stocks: The True Measure of Stock Valuation
United Laboratories International Holdings (OTCPK:ULIHF) Cyclically Adjusted PB Ratio Explanation
Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.
United Laboratories International Holdings Cyclically Adjusted PB Ratio Related Terms
United Laboratories International Holdings Cyclically Adjusted PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
United Laboratories International Holdings Cyclically Adjusted PB Ratio Chart
United Laboratories International Holdings Annual Data
ULIHF vs ZTS: Cyclically Adjusted PB Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, United Laboratories International Holdings's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
United Laboratories International Holdings Cyclically Adjusted PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, United Laboratories International Holdings's Cyclically Adjusted PB Ratio distribution charts can be found below:
* The bar in red indicates where United Laboratories International Holdings's Cyclically Adjusted PB Ratio falls into.
United Laboratories International Holdings Cyclically Adjusted PB Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PB Ratio of 1.19 mean?
United Laboratories International Holdings (ULIHF) has a Cyclically Adjusted PB Ratio of 1.19 as of Aug. 20, 2026. Cyclically Adjusted PB Ratio is the ratio of share price to a company's inflation-adjusted book value per share over a 10-year period. View historical data on United Laboratories International Holdings and its competitors. This is 14% below median its historical median of 1.38. Over the past decade, United Laboratories International Holdings' Cyclically Adjusted PB Ratio has ranged from 0.68 to 3.03. According to the industry distribution chart, United Laboratories International Holdings ranks #279 out of 690 companies in the Drug Manufacturers industry, placing it in the top 40.4%.
Is United Laboratories International Holdings' Cyclically Adjusted PB Ratio too high?
United Laboratories International Holdings' current Cyclically Adjusted PB Ratio of 1.19 is 14% below median its 10-year median of 1.38. Over the past 10 years, this metric has ranged from a low of 0.68 to a high of 3.03. The Drug Manufacturers industry median Cyclically Adjusted PB Ratio is 1.74. United Laboratories International Holdings' value of 1.19 is 31.6% below this industry median. Based on the distribution chart, United Laboratories International Holdings ranks #279 out of 690 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, United Laboratories International Holdings has a GF Score™ of 90/100, reflecting its overall financial health beyond just this single metric.
How does United Laboratories International Holdings' Cyclically Adjusted PB Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, United Laboratories International Holdings ranks #279 out of 690 companies for Cyclically Adjusted PB Ratio. This puts United Laboratories International Holdings in the upper half of its industry. The industry median Cyclically Adjusted PB Ratio is 1.74. United Laboratories International Holdings' value of 1.19 is 31.6% below this benchmark. Historically, United Laboratories International Holdings' own Cyclically Adjusted PB Ratio has ranged from 0.68 to 3.03 over the past decade. While the company's 10-year median is 1.38 vs. the industry median of 1.74, United Laboratories International Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PB Ratio for a Drug Manufacturers company?
The median Cyclically Adjusted PB Ratio among Drug Manufacturers companies is 1.74, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. United Laboratories International Holdings's current Cyclically Adjusted PB Ratio of 1.19 is 31.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PB Ratio mean?
A high Cyclically Adjusted PB Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PB Ratio is the ratio of share price to a company's inflation-adjusted book value per share over a 10-year period. View historical data on United Laboratories International Holdings and its competitors. For the Drug Manufacturers industry, the median Cyclically Adjusted PB Ratio is 1.74 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. United Laboratories International Holdings's current Cyclically Adjusted PB Ratio is 1.19, which is 14% below median its own 10-year median of 1.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is United Laboratories International Holdings stock overvalued right now?
United Laboratories International Holdings (ULIHF) has a current Cyclically Adjusted PB Ratio of 1.19. The stock's GF Value™ is $1.24, compared to a current price of $1.24 — trading right at its estimated fair value. The current Cyclically Adjusted PB Ratio is 1.19, which is 14% below median its 10-year median of 1.38 and 31.6% below the Drug Manufacturers industry median of 1.74. United Laboratories International Holdings' overall GF Score™ is 90/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PB Ratio calculated?
Cyclically Adjusted PB Ratio is calculated from a company's financial statements. For United Laboratories International Holdings (ULIHF), the current Cyclically Adjusted PB Ratio is 1.19 as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is United Laboratories International Holdings (ULIHF) Overvalued in 2026?
Based on GuruFocus' analysis, United Laboratories International Holdings stock appears to be undervalued.
The current stock price of $1.24 is trading 0% below its estimated GF Value™ of $1.24.
Key valuation signals for ULIHF:
Cyclically Adjusted PB Ratio: 1.19 (14% below median its 10-year median of 1.38)
GF Value™: $1.24 vs. price of $1.24 (0% below fair value)
Industry Position: 31.6% below the Drug Manufacturers median (#279 of 690)
No single metric tells the full story. See the ULIHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
United Laboratories International Holdings Ltd is mainly engaged in the research and development, production and sales of pharmaceuticals. The company operates in three segments: Intermediate products, Bulk medicine, and Finished products. The company's Finished products segment includes antibiotic products, insulin series products, and other medicines. The vast majority of the company's revenue is derived from its Finished products segment, followed by Bulk medicine. The majority of the company's sales are generated in China, followed by Europe, India and other countries.
90GF Score
Get the complete analysis for ULIHF
Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ULIHF has been successfully added to your 
